[Tumor-suppression effect of polyactin A combined with GM-CSF, TNF-alpha and IL-4 on cord blood mononuclear cells].
OBJECTIVE
To investigate the tumor-suppression effect of PA combined with GM-CSF, TNF-alpha and IL-4 on cord blood mononuclear cells (CBMC).


METHODS
The mononuclear cells were isolated from human umbilical cord blood and cultured with polyacttin A (PA), GM-CSF + TNF-alpha + IL-4 (GTI), and GTI + PA (GTIP) respectively. Six days later, surface antigen expression of the cultured cells, including CD1a and CD83, which were the specialized markers of dendritic cell (DC), were analyzed by immunohistochemistry technique. The CBMC were cultured with GTI for 24 h to enhance DC, then were added apoptotic/necrotic Hela/HepG2 tumor cells, and finally PA was co-cultured. The antitumor cytotoxicity of CBMC was measured by MTT assay.


RESULTS
After the culture, CD1a and CD83 positive cell rates of the PA group inreased significantly, reaching (19.63 +/- 3.61)%, (9.28 +/- 4.31) % respectively, much higher than that of the control, but lower than that of the GTI group. The killing rate to the tumor cells of CBMC cultured with GTIP increased remarkably, much higher than the control, GTI and PA groups. After tumor antigens were added to the CBMC of GTIP group (GTIP + Tc), the killing rate increased.


CONCLUSIONS
PA not only promotes the proliferation and maturation of cord blood derived DC, but also improves the tumor-suppression effect of CBMC cultured with GTI.
Dong
Wei-Jiang
WJ
Department of Anatomy and Histology, Medical College of Xi'an Jiaotong University, Xi'an, China. dongwj@mail.xjtu.edu.cn
Hu
Hai-Tao
HT
Gong
Hui-Li
HL
D015703:Antigens, CD / Q000096:biosynthesis / Q000235:genetics; D018949:Antigens, CD1 / Q000096:biosynthesis / Q000235:genetics; D002478:Cells, Cultured; D005312:Fetal Blood / Q000166:cytology; D006020:Glycopeptides / Q000494:pharmacology*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology*; D006367:HeLa Cells; D006801:Humans; D007136:Immunoglobulins / Q000096:biosynthesis / Q000235:genetics; D007167:Immunotherapy; D015847:Interleukin-4 / Q000494:pharmacology*; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology*; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy; D008562:Membrane Glycoproteins / Q000096:biosynthesis / Q000235:genetics; D009369:Neoplasms / Q000628:therapy*; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D000097802:CD83 Antigen
D015703:Antigens, CD; D018949:Antigens, CD1; D006020:Glycopeptides; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D007136:Immunoglobulins; D015847:Interleukin-4; D008562:Membrane Glycoproteins; D014409:Tumor Necrosis Factor-alpha; D000097802:CD83 Antigen; C064233:polyactin A